ArticleDiseases (Basel, Switzerland)2026
Burden and Clinical Impact of Hepatitis D Virus Co-Infection Among HBsAg-Positive Patients in Mauritania.
Article in Diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B virus (HBV) infection remains highly endemic in sub-Saharan Africa, where hepatitis delta virus (HDV) co-infection substantially worsens liver disease outcomes. Mauritania has long been suspected to be a high-burden setting for HBV-HDV co-infection, yet contemporary data describing its clinical and virological impact remain limited.
methodsWe conducted a hospital-based cross-sectional study at the National Institute of Hepato-Virology (INHV) in Nouakchott, including 401 HBsAg-positive patients. Demographic, clinical, biological, and virological data were collected. HDV serology and RNA testing were performed when available. Liver disease severity, including cirrhosis and hepatocellular carcinoma (HCC), was assessed using clinical, biological, and imaging criteria.
resultsHDV antibodies were detected in 31.9% of HBsAg-positive patients, confirming Mauritania as a hyper-endemic area for HDV. HDV co-infection was strongly associated with advanced liver disease, with HDV antibodies present in 86.4% of cirrhotic patients and 82.4% of those with HCC. Patients with HDV infection frequently exhibited suppressed HBV DNA levels, reflecting viral interference. A substantial proportion of patients presented with decompensated cirrhosis or HCC at diagnosis, and nearly 70% were treatment-naïve. Overall, HDV co-infection emerged as the principal driver of severe liver disease in this cohort.
conclusionsHBV/HDV co-infection is highly prevalent in Mauritania and is associated with a wide clinical spectrum ranging from asymptomatic infection to decompensated cirrhosis and hepatocellular carcinoma. HDV co-infection is the principal driver of severe liver disease, often occurring despite low or undetectable HBV DNA levels. Systematic HDV screening among all HBsAg-positive individuals is urgently needed to improve risk stratification, guide therapeutic decisions, and reduce liver-related morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.